Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cobimetinib and vemurafenib for the treatment of melanoma.

Expert opinion on pharmacotherapy - 1 Jan 2016

Boespflug Amélie, Thomas Luc

Abstract excerpt

INTRODUCTION: Cobimetinib combined with vemurafenib is a new approved MEK inhibitor for first line treatment of metastatic melanoma patients with BRAF V600 mutations. It improves tumor response rates and progression free survival compared to vemurafenib alone, while decreasing toxicities due to the paradoxical activation of the MAPK signaling pathway. AREAS COVERED: This review covers the pharmacology, efficacy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azetidines
Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Piperidines

Share to Vemurafenib

Source

Identifiers

PMID: 26999478
DOI: 10.1517/14656566.2016.1168806

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cobimetinib and vemurafenib for the treatment of melanoma.PMID 26999478Read ↗

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.Semantic proximity Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Semantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.Semantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.